Panel Discussion: Co-development of Drugs and Companion Diagnostics

Presented at Drug Discovery 2018: [ Ссылка ]

Speaker: Annette Gilchrist, PhD, Martin Shaw, Thomas Webster, PhD

Agnete B. Fredriksen is Co-Founder and joined Vaccibody in 2007. She holds a MSc, PhD from Institute of Immunology, Rikshospitalet Medical Center in Oslo where she designed and developed the first Vaccibody vaccine molecules. She received the King's Gold Medal for her PhD thesis describing Vaccibodies. Her focus is on cancer vaccines from idea to clinical development…

Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as qualified for use in toxicological testing. He developed strong relationships with hospitals, clinical research organizations and pharmaceutical companies, including AstraZeneca, Sanofi Aventis, Pfizer, Novartis, Merck, Glaxo Smith Kline and Johnson and Johnson…

Thomas J. Webster's (H index: 80, Google Scholar) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995) and in biomedical engineering from Rensselaer Polytechnic Institute (M.S., 1997; Ph.D., 2000). Prof. Webster is the current director of the Nanomedicine Laboratories (currently at 23 members) and has completed extensive studies on the use of nanophase materials in medicine. He pioneered the use of nanomaterials to increase tissue growth, inhibit infection, and decrease inflammation. He was appointed Department Chair of Chemical Engineering at Northeastern University in 2012 in which the Department recently broke the record for the fastest increase in ranking over a five year period from the U.S. News and World Report. In his 17 years in academics, Prof. Webster has graduated/supervised over 149 visiting faculty, clinical fellows, post-doctoral students, and thesis completing B.S., M.S., and Ph.D. students...

Panel Discussion: Co-development of Drugs and Companion Diagnostics

The distinction between "complementary" and "companion" diagnostics tests confuse many physicians and healthcare professionals. Panelists Professor Thomas Webster (Northeastern University) and Dr. Martin Shaw (AroCell AB) will discuss the differences between "complementary" and "companion" diagnostics and why both are important

Earn PACE/CME Credits:
1. Make sure you’re a registered member of LabRoots: [ Ссылка ]
2. Watch the webinar on YouTube or on the LabRoots Website: [ Ссылка ]
3. Click Here to get your PACE expires 5/21/2018: [ Ссылка ]

LabRoots on Social:
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
Instagram: [ Ссылка ]
Pinterest: [ Ссылка ]
SnapChat: labroots_inc

свернуть